The University of Chicago Header Logo

Connection

Peter O'Donnell to Pharmacogenomic Testing

Back to Details
This is a "connection" page, showing publications Peter O'Donnell has written about Pharmacogenomic Testing.
Peter O'Donnell
Connection Strength
7.811
Pharmacogenomic Testing
  1. Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation. Clin Transl Sci. 2026 04; 19(4):e70537.
    View in: PubMed
    Score: 0.877
  2. Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing. Clin Transl Sci. 2025 04; 18(4):e70193.
    View in: PubMed
    Score: 0.818
  3. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
    View in: PubMed
    Score: 0.656
  4. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
    View in: PubMed
    Score: 0.635
  5. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200.
    View in: PubMed
    Score: 0.606
  6. Incorporating preemptive pharmacogenomic testing into the clinical setting. Clin Adv Hematol Oncol. 2020 09; 18(9):526-529.
    View in: PubMed
    Score: 0.595
  7. Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. Clin Transl Sci. 2020 01; 13(1):78-87.
    View in: PubMed
    Score: 0.558
  8. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
    View in: PubMed
    Score: 0.557
  9. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
    View in: PubMed
    Score: 0.554
  10. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics. 2017 05; 27(5):179-189.
    View in: PubMed
    Score: 0.472
  11. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.470
  12. Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clin Pharmacol Ther. 2025 10; 118(4):906-916.
    View in: PubMed
    Score: 0.208
  13. A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information. Clin Pharmacol Ther. 2025 06; 117(6):1793-1802.
    View in: PubMed
    Score: 0.203
  14. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
    View in: PubMed
    Score: 0.153
  15. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827.
    View in: PubMed
    Score: 0.137
  16. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.133
  17. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
    View in: PubMed
    Score: 0.133
  18. Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.